The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6376-6380

  Wu, Kendall ^a   Zhang, Yun ^a   Xu, Xiao Chun ^b   Hill, Jamal ^a   Celestino, Joseph ^a   Kim, Hee Tae ^a   Mohsin, Syed K ^a   Hilsenbeck, Susan G ^a   Lamph, William W ^c   Bissonette, Reid ^c   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; ESTROGEN RECEPTOR; RALOXIFENE; RETINOID X RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER PREVENTION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL DIVISION; FEMALE; GENE EXPRESSION; GENES, ERBB-2; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; RECEPTORS, ESTROGEN; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS; TRANSGENES;

EID: 0037112520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fisher, B., Constantino, J., Wickerham, D., Redmond, C., Kavanah, M., Cronin, W., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford. L., Wolmark, N., and other NSABP investigators. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998
2. Cummings, S., Eckert, S., Krueger, K., Grady, D., Powles, T., Cauley, J., Norton, L., Nickelsen, T., Bjarnason, N., Morrow, M., Lippman, M., Black, D., Glusman, J., Costa, A., and Jordan, V. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. J. Am. Med. Assoc., 281: 2189-2197, 1999
3. Aranda. A., and Pascual, A. Nuclear hormone receptors and gene expression. Physiol. Rev., 81: 1269-1304. 2001
4. Yang. L., Kim, H., Munoz-Medellin, D., Reddy, P., and Brown. P. H. Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res., 57: 4652-4661, 1997
5. Rubin, M., Fenig, E., Rosenauer, A., Menendez-Botet, C., Achkar, C., Bentel, J. M., Yahalom, J., Mendelsohn, J., Wilson, H., and Miller, J. 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res., 54: 6549-6556, 1994
6. Anzano, M. A., Byers, S. W., Smith. J. M., Peer, C. W., Mullen, L. T., Brown, C. C., Roberts, A. B., and Sporn. M. B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res., 54: 4614-4617, 1994
7. Wu, K., Kim, H., Rodriquez, J. L., Munoz-Medellin, D., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Gottardis, M. M., Shirley, M. A., Kuhn, J. G., Green, J. E., and Brown, P. H. 9-cis retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin. Cancer Res., 6: 3696-3704, 2000
8. Green, J., Shibata, M., Yoshidome, K., Liu, M., Jorcyk, C., Anver, M., Wigginton, J., Wiltrout, R., Shibata, E., Kaczmarczyk, S., Wang, W., Liu, Z., Calvo, A., and Couldrey. C. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene, 19: 1020-1027, 2000
9. Miller, V. A., Rigas, J. R., Benedetti, F. M., Verret. A. L., Tong, W. P., Kris, M. G., Gill, G. M., Loewen. G. R., Truglia. J. A., Ulm. E. H., and Warrell, R. P., Jr. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin. Cancer Res., 2: 471-475, 1996
10. Wu, K., Kim, H. T., Rodriquez, J. L., Hilsenbeck, S. G., Mohsin, S. K., Xu, X. C., Lamph, W. W., Kuhn, J. G., Green, J. E., and Brown, P. H. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomark. Prey., 11: 467-474, 2002
11. Guy, C. T., Webster. M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992
12. Steeg. P. S., and Zhou, Q. Cyclins and breast cancer, Breast Cancer Res. Treat., 52: 17-28, 1998
13. Gottardis, M. M., Bischoff, E. D., Shirley, M. A., Wagoner, M. A., Lamph, W. W., and Heyman, R. A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand. Cancer Res., 56: 5566-5570, 1996
14. Ki, M. H., Paik, K. J., Lee, J. H., Chung, H. Y., Lee, K. H., Kim, K. W., and Kim, N. D. All-trans retinoic acid induced differentiation of rat mammary epithelial cells cultured in serum-free medium. Arch. Pharm. Res., 21: 298-304, 1998
15. Agarwal, V. R., Bischoff. E. D., Hermann, T., and Lamph. W. W. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (Targretin). Cancer Res., 60: 6033-6038, 2000
16. Anzano, M. A., Peer, C. W., Smith, J. M., Mullen, L. T., Shrader, M. W., Logsdon. D. L., Driver, C. L., Brown. C. C., Roberts, A. B., and Sporn, M. B. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. (Bethesda), 88: 123-125, 1996
17. Bischoff, E. D., Gottardis, M. M., Moon, T. E., Heyman, R. A., and Lamph, W. W. Beyond tamoxifen: The retinoid X receptor-selective ligand LGDI069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res., 58: 479-484, 1998
18. Bischoff, E. D., Heyman, R. A., and Lamph, W. W. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J. Natl. Cancer Inst. (Bethesda), 91: 2118, 1999
19. Suh, N., Lamph, W., Glasebrook, A., Grese, T., Palkowitz, A., Williams, C., Risingsong, R., Farris, M., Heyman. R., and Sporn, M. Prevention and treatment of experimental breast cancer with combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res., 8: 3270-3275, 2002
20. Miller, V. A., M. Benedettu, F., Rigas, J. R., Verret, A. L., Pfister, D. G., Strauss, D., Kris. M. G., Crisp, M., Heyman, R., Loewen, G. R., Truglia, J. A., and Raymond, P. Warrell, J. Initial clinical trial of a selective retinoid x receptor ligand, LGD1069. J. Clin. Oncol., 15: 790-795, 1997
21. Rizvi, N. A., Marshall. J. L., Dahut, W., Ness, E., Truglia, J. A., Loewen, G., Gill, G. M., Ulm. E. H., Geiser, R., Jaunakais, D., and Hawkins, M. J. A Phase I study of LGD1069 in adults with advanced cancer. Clin. Cancer Res., 5: 1658-1664, 1999
22. Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., and Yocum, R. C. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J. Clin. Oncol., 19: 2456-2471, 2001